Chimeric antigen T cell receptor treatment in hematological malignancies

Affiliations

Natasha Ali et al. Blood Res. 2019 Jun.

. 2019 Jun;54(2):81-83.

doi: 10.5045/br.2019.54.2.81. Epub 2019 Jun 25.

¹ Department of Pathology and Laboratory Medicine/Oncology, Aga Khan University, Karachi, Pakistan.

No abstract available

Conflict of interest statement

Authors' Disclosures of Potential Conflict of Interest: No potential conflict of interests relevant to article were reported.

A Primer on Chimera Associated Receptor T-Cells.
Muthineni S, Zink K, Kambhampati S. Muthineni S, et al. Mo Med. 2021 Sep-Oct;118(5):460-465. Mo Med. 2021. PMID: 34658441 Free PMC article. Review.
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment.
Titov A, Valiullina A, Zmievskaya E, Zaikova E, Petukhov A, Miftakhova R, Bulatov E, Rizvanov A. Titov A, et al. Cancers (Basel). 2020 Jan 3;12(1):125. doi: 10.3390/cancers12010125. Cancers (Basel). 2020. PMID: 31947775 Free PMC article. Review.
Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy.
Tahmasebi S, Elahi R, Khosh E, Esmaeilzadeh A. Tahmasebi S, et al. Clin Transl Oncol. 2021 Jun;23(6):1003-1019. doi: 10.1007/s12094-020-02490-9. Epub 2020 Sep 30. Clin Transl Oncol. 2021. PMID: 32997278 Review.
Immune Therapy for Liver Cancers.
Hilmi M, Vienot A, Rousseau B, Neuzillet C. Hilmi M, et al. Cancers (Basel). 2019 Dec 27;12(1):77. doi: 10.3390/cancers12010077. Cancers (Basel). 2019. PMID: 31892230 Free PMC article. Review.
Aging and immunotherapies: New horizons for the golden ages.
Hamilton JAG, Henry CJ. Hamilton JAG, et al. Aging Cancer. 2020 Dec;1(1-4):30-44. doi: 10.1002/aac2.12014. Epub 2020 Sep 30. Aging Cancer. 2020. PMID: 35874875 Free PMC article.

1. Bartenstein M, Deeg HJ. Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am. 2010;24:407–422. - PMC - PubMed
1. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720–724. - PMC - PubMed
1. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35–45. - PubMed
1. Wohlfarth P, Worel N, Hopfinger G. Chimeric antigen receptor TXMLLink_XYZcell therapy-a hematological success story. Memo. 2018;11:116–121. - PMC - PubMed
1. Locke FL, Ghobadi A, Jacobson CA, et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. J Clin Oncol. 2018;36(Suppl):abst 3003.